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S-Nitrosylation of protein cysteine thiol is a post-translational modification 
mediated by nitric oxide (NO). The overproduction of NO causes nitrosative stress, 
which is known to induce endoplasmic reticulum (ER) stress. We previously reported 
that S-nitrosylation of protein disulfide isomerase (PDI) and the ER stress sensor 
inositol-requiring enzyme 1 (IRE1) decreases their enzymatic activities. However, it 
remains unclear whether nitrosative stress affects ER-associated degradation (ERAD), a 
separate ER stress regulatory system responsible for the degradation of substrates via 
the ubiquitin-proteasomal pathway. 
In the present study, we found that the ubiquitination of a known ERAD substrate, 
serine/threonine-protein kinase 1 (SGK1), is attenuated by nitrosative stress. C-terminus 
of Hsc70-interacting protein (CHIP) together with ubiquitin-conjugating enzyme E2 D1 
(UBE2D1) are involved in this modification. We detected that UBE2D1 is S-
nitrosylated at its active site, Cys85 by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Furthermore, in vitro and cell-based experiments revealed 
that S-nitrosylated UBE2D1 has decreased ubiquitin-conjugating activity. 
Our results suggested that nitrosative stress interferes with ERAD, leading to 
prolongation of ER stress by co-disruption of various pathways, including the molecular 
chaperone and ER stress sensor pathways. Given that nitrosative stress and ER stress 
are upregulated in the brains of patient with Parkinson’s disease (PD) and of those with 
Alzheimer’s disease (AD), our findings may provide further insights into the 






NO is a gaseous molecule with a short half-life [1,2]. NO is generated by nitric 
oxide synthase (NOS), an enzyme that synthesizes NO from L-arginine using nicotine 
dinucleotide phosphate (NADPH) and oxygen. NO possesses a free radical moiety that 
reacts posttranslationally with the cysteine thiols of proteins to form S-nitrosothiol. 
Previous studies have reported that S-nitrosylated (SNO-) proteins exhibit altered 
enzymatic activity, localization, and/or structure [3,4]. Physiological levels of NO have 
been shown to regulate apoptosis, neurotransmission, and cell proliferation [5–7]. On 
the other hand, excessive amounts of NO cause nitrosative stress and contribute to the 
pathogenesis of various diseases, including neurodegenerative disorders, cancer, and 
diabetes[8–10]. 
How does nitrosative stress affect such diseases? The answer may come from the 
association of nitrosative stress with ER stress. ER stress is induced by the 
accumulation of unfolded proteins at the ER. During ER stress events, three different 
sensors, activating transcription factor 6 (ATF6), IRE1, and PKR-like ER kinase 
(PERK), are activated to deal with this stress. Following the activation of ER stress 
sensors, the molecular chaperone genes such as PDI are upregulated to help protein 
folding and ERAD finally to degrade unfolded protein by the ubiquitin-proteasome 
system. We previously reported that S-nitrosylation of PDI and IRE1 attenuates their 
enzymatic activities and induced severe ER stress[8,11]. 
These lines of evidence support that NO is the modulator for ER stress, however its 
effect on ERAD remains unclear. Here, we showed that the ubiquitination of a known 
ERAD substrate, SGK1, is attenuated by nitrosative stress. Further analysis revealed 
that the active site of ERAD-associated UBE2D1 is target for S-nitrosylation, which 
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may decrease ubiquitin-conjugating activity. Our findings will shed light on the 
unknown modulatory effect of NO on ERAD and this might be the key to understanding 
the pathogenesis of nitrosative stress-related disorders. 
 
2. Material and methods 
2.1 Reagents and antibodies 
The in vitro ubiquitination assay was performed using the CHIP/Luciferase 
Ubiquitination Kit (Boston Biochem, K-280, Lot #16559217) and Human recombinant 
UBE2D1 (Boston Biochem, E2-616). The following antibodies were purchased from 
the indicated vendors: anti-Myc antibody (Cell Signaling Technology, #2276), anti-Akt 
antibody (Cell Signaling Technology, #9272S), anti-phospho-Akt (S473) (D9E) XP(R) 
antibody (Cell Signaling Technology, #4060), anti-GAPDH antibody (Cell Signaling 
Technology, #2118), anti-FLAG antibody (Sigma-Aldrich, A8592), anti-ubiquitin 
antibody (Sigma-Aldrich, MAB1510), anti-T7 antibody (MBL, PM022), anti-goat IgG-
HRP (Santa Cruz Biotechnology, sc-2354), anti-mouse IgG-HRP (GE Healthcare, 
NA9310), and anti-rabbit IgG-HRP (GE Healthcare, NA9340). 
 
2.2 Cell culture 
Human embryonic kidney (HEK) 293T cells and were cultured in Dulbecco's 
modified Eagle's medium containing 10% (v/v) heat-inactivated fetal calf serum at 37C 
in a humidified atmosphere of 5% CO2/95% air. 
 
2.3 Construction of plasmids 
The cDNAs encoding the UBE2D1 and SGK1 proteins were derived from the 
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Genome Network Project (RIKEN BRC) clones HGY088581 and HGX001612, 
respectively [12]. The UBE2D1 cDNA was amplified by Tks Gflex™ DNA Polymerase 
(TaKaRa Bio, R060A) using the following primer pair: 5'-AAA GCG GCC GCG ATG 
GCG CT-3' and 5'-CCC GGG ATC CTT ACA TTG C-3'. The resulting PCR product 
was digested with BamHI and NotI and subcloned into the similarly digested 
p3×FLAG-CMV10 vector (Sigma-Aldrich, E7658). The SGK1 cDNA was amplified by 
Tks Gflex™ DNA Polymerase (TaKaRa Bio, R060A) using the following primer pair: 
5’-CCC CGG ATC CCC ACC ATG ACG GTG AAA ACT GAG-3’ and 5’-GGG CTC 
GAG GAG GAA AGA GTC CGT GGG-3’. The resulting PCR product was digested 
with BamHI and XhoI and subcloned into the similarly digested pcDNA™6 myc-His 
vector (Thermo Fisher Scientific, V22120). The inserted sequences were confirmed by 
the Sanger sequencing.  
 
2.4 MG132 and LY294002 treatment 
HEK293T cells were transfected pcDNATM6-myc-His SGK1. At 24hr after 
transfection, cells were treated with the proteasome inhibitor MG132 (CEM, CS-0471; 
at 5 or 25 M) or the autophagy inhibitor LY294002 (CAY, 70920; 5 or 10 M) for 3 hr.  
 
2.5 Immunoprecipitation  
  To examine the ubiquitination levels of SGK1, HEK293T cells transfected with the 
myc-SGK1 were solubilized using Immunoprecipitation buffer (phosphate-buffered 
saline (PBS) containing 1% NP-40, 0.5% deoxycholic acid sodium salt, 0.1% sodium 
dodecyl sulfate (SDS), 0.5 mM ethylenediaminetetraacetic acid (EDTA), 5 mM N-
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ethylmaleimide, 1 mM NaF, and protease inhibitor cocktail (Roche)) and centrifuged at 
20400 × g for 10 min at 4C. The supernatant then was treated with an anti-Myc 
antibody, and bond proteins were immunoprecipitated by binding to Protein G 
Sepharose 4 Fast Flow beads (GE Healthcare, 17061801) prepared as follow. In brief, 
the beads were pretreated with 1% bovine serum albumin (BSA) for 1 hr to block non-
specific binding, and then washed three times with Neutralization buffer (20 mM 
HEPES (pH 7.7), 100 mM NaCl, 1 mM EDTA, and 0.5% Triton X-100). The blocked 
beads were combined with cell lysates and incubated overnight at 4C. The beads then 
were recovered and washed five times with Neutralization Buffer. Bound proteins were 
eluted from the beads using Laemmli sample buffer (62.5mM Tris-HCl (pH 6.8), 10% 
glycerol, 5% 2-mercaptoethanol, and 2% SDS) and analyzed by western blotting. 
 
2.6 Western blot analysis 
Cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 1% 
Triton-X, 0.1% SDS, and 1% sodium deoxycholate supplemented with protease 
inhibitor cocktail (Roche)) or Immunoprecipitation buffer. Each sample was boiled in 
Laemmli buffer and analyzed by western blotting as described previously [13]. The 
quantification analysis of [Ub]n-SGK1, SNO-UBE2D1, and [Ub]n-Luciferase was 
performed using Image J software (NIH, version 1.51j8). 
 
2.7 Biotin-switch assay  
SNOC-exposed HEK293T cells were subjected to the biotin-switch assay, as 
previously described [13]. Briefly, cells were lysed in ice-cold HEN buffer (250 mM 
HEPES-NaOH (pH 7.7), 1 mM EDTA, 0.1 mM neocuproine) containing 1% Triton X-
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100 and protease inhibitor cocktail (Roche). Aliquots (800 g total protein each) were 
subjected to the biotin-switch assay. Samples were stirred with blocking buffer (9 
volumes of HEN buffer plus 1 volume 25% SDS, adjusted to 25 mM S-methyl 
methanethiosulfonate (MMTS) with a 2 M stock prepared in dimethylformamide 
(DMF)) and incubated for 20 min at 50C to block free cysteine residues. Acetone 
precipitation was performed to remove excess MMTS, and nitrosothiols were reduced 
by 12.5 mM ascorbic acid to permit reaction with the sulfhydryl-specific biotinylation 
reagent HPDP-biotin (Thermo Fisher Scientific, 21341). Biotinylated proteins were 
pulled down using streptavidin agarose beads (Thermo Fisher Scientific, 20353), and 
western blot analysis was performed. 
 
2.8 LC-MS/MS 
HEK293T cells were treated with 200 M SNOC for 30 min. Total cell lysates 
were then subjected to biotin-switch assay. Pull-down samples were treated with 0.25 
g/mL trypsin (Promega) overnight at 37C, and the digested peptides were cleaned-up 
using self-made C18 and SCX (3M Empore solid phase extraction disk) stage tips. The 
sample was subjected to liquid chromatography using an EASY-nLC 1000 instrument 
(Thermo Fisher Scientific) coupled with a Q-Exactive hybrid quadrupole-orbitrap mass 
spectrometer (MS, Thermo Fisher Scientific) with a nanospray ion source in positive 
mode. The processed peptides were separated using a nano-HPLC C18 capillary column 
(0.075 × 150 mm, 3 m) (Nikkyo Technos). A 60-min gradient was used at a flow rate 
of 300 nL/min, including 5–35% Bin over 48 min and then 35–65% Bin over 12 min 
(solvent A, 0.1% formic acid; solvent B, 100% CH3CN, 0.1% formic acid). The 
resulting MS and MS/MS data were used to search the Swiss Prot database using 
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Proteome Discoverer (Thermo Fisher Scientific) with MASCOT search engine software 
(Matrix Science). 
 
2.9 In vitro ubiquitination assay 
The CHIP/Luciferase Ubiquitination Kit and human recombinant UBE2D1 were 
used to detect the direct effect of NO on UBE2D1 enzyme activity. An in vitro 
ubiquitination assay was carried out according to the manufacturer's instructions except 
for enzyme pre-treatment. Specifically, we pre-treated 1 M UBE2D1 with SNOC (at 1, 
10, or 50 M) or decayed (old) SNOC (50 M) in the dark for 2 hr at room temperature.  
  
2.10 Statistical analysis 
All experiments were repeated independently for a total of at least three times. All 
data are presented as the mean ± standard error of the mean (S.E.M.). Statistical 
comparisons were carried out using two-tailed non-paired Student's t-tests or one-way 
ANOVA with post hoc Bonferroni's test using Graphpad Prism 8 software (Graphpad 
Software). p values of <0.05 were considered significant.   
 
3.  Results 
3.1 NO inhibits the ubiquitination of SGK1, ERAD substrate. 
We and other groups have reported that molecular chaperones and ER stress 
sensors are targets for NO [8, 10, 11, 14]; however, the effect of NO on ERAD remains 
largely unknown. To explore this issue, we focused on SGK1, a well-known ERAD 
substrate that has a short half-life (about 30 min) [15]. 
To confirm whether SGK1 is degraded by the ubiquitin-proteasome system, we 
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transiently transfected HEK293T cells with a SGK1 and treated the resulting cells with 
a proteasome inhibitor (MG132) or with an autophagy inhibitor (LY294002). We 
confirmed the phosphoinositide-3 kinase (PI3K) inhibitory effect of LY294002 by 
monitoring Akt phosphorylation. As expected, MG132, but not LY294002, inhibited the 
degradation of SGK1 (Fig. 1A).  
To monitor whether nitrosative stress affects the ubiquitination of SGK1, we co-
transfected HEK293T cells with both Myc-SGK1 and T7-ubiquitin and treated the 
resulting cells with either of two different physiological NO donors, S-nitrosocysteine 
(SNOC) or S-nitrosoglutathione (GSNO). Lysates of the treated cells then were 
subjected to immunoprecipitation to purify SGK1, and the resulting protein was 
assessed for ubiquitination. Probing of the western blots with anti-Myc antibody 
revealed the presence of three distinct non-ubiquitinated protein bonds. We speculated 
that these three bands correspond to post-translationally modified versions of SGK1; 
notably, previous work has identified several potential phosphorylation sites within 
SGK1 [16]. Interestingly, we found that polyubiquitination of SGK1 was significantly 
decreased by both SNOC and GSNO treatments (Fig. 1B and C, respectively). These 
results indicated that nitrosative stress has an inhibitory effect on the ubiquitination of 
SGK1. 
 
3.2. Identification of Cys85 of UBE2D1 as the target site of S-nitrosylation. 
Given that NO regulates the enzymatic activity of proteins via S-nitrosylation, a 
post-translational modification [8, 10, 11, 14, 17], we hypothesized that NO similarly 
would modulate components of the ERAD. To test this prediction, we subjected SNOC-
treated HEK293T cells lysates to a biotin-switch assay, which permits biotinylation of 
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S-nitrosylated moieties [18], and used the biotin label to purify the S-nitrosylated 
proteins. We analyzed the resulting proteins using LC-MS/MS. This analysis identified 
UBE2D1, a known component of the ubiquitin-proteasome system [19, 20], as a novel 
target for modification by NO. Notably, the MS/MS spectrum of the y6 peptide 
indicated a mass shift (+428) consistent with the biotin to the cysteine residue of the y5 
peptide, indicating that Cys85 of UBE2D1 is the residue targeted by S-nitrosylation 
(Fig. 2A). UBE2D1 plays an important role as an upstream regulator of CHIP, which 
itself regulates ERAD by serving as an E3 ubiquitin ligase. Also, this system is involved 
in the degradation of SGK1 [19–23]. The previously published 3D structure of the 
interaction between ubiquitin and UBE2D1 (PDB:3PTF, https://www.rcsb.org/, [24]) is 
shown in Fig. 2B. In the figure, the red circle shows the non-covalent bond between 
ubiquitin and Cys85 of UBE2D1, suggesting that this region is important for this 
enzyme’s activity. To further confirm S-nitrosylation of UBE2D1, we used SNOC 
treated HEK293T cells overproducing FLAG-UBE2D1. Further biotin-switch analysis 
demonstrated that UBE2D1 indeed undergoes S-nitrosylation in a NO-donor-dose-
dependent manner (Fig. 2C, D). 
Based on these lines of evidence, we hypothesized that Cys85 of UBE2D1 is a 
target site for NO, and that S-nitrosylation of this site may decrease the ubiquitination of 
substrates, thereby downregulating the ERAD pathway. 
 
3.3 NO donor treatment attenuates the ubiquitin-conjugating activity of UBE2D1  
    To test our hypothesis, we performed an in vitro UBE2D1 ubiquitin-conjugating 
activity assay using luciferase as the target protein to assess the effect of pretreating 
recombinant UBE2D1 with SNOC (Fig. 3A). Following the reaction, we tested the 
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assay products by immunoblotting with anti-ubiquitin (Fig. 3B) or anti-luciferase 
antibodies (Fig. 3C) to detect the ubiquitination of the substrate (luciferase). 
Intriguingly, we found that pre-treatment with SNOC inhibited the ubiquitination of 
luciferase in a dose-dependent manner (Fig. 3B, 3C). Figure 3D shows the 
quantification analysis of the gel shown in Fig. 3C. To measure UBE2D1’s 
ubiquitination efficacy, we quantified high-molecular-weight (> 70-kDa) signals, that is, 
products that exceeded the predicted size of monoubiquitinated luciferase. The data 
showed that the ubiquitination activity of UBE2D1 was significantly decreased by 
pretreatment with SNOC at 10 and 50 M. 
 
4. Discussion 
Several studies have indicated that the NO is an important regulator of various 
cellular processes [5–7]. However, excess NO levels can cause various diseases, 
including neurodegenerative diseases, cancer, and diabetes [8-10]. Notably, both the 
accumulation of the unfolded proteins and excessive amounts of NO are observed in the 
brains of patients with neurodegenerative diseases [25,26]. In previous work, we 
demonstrated that nitrosative stress exacerbates ER stress via S-nitrosylation of the 
molecular chaperone PDI [8] and the ER stress sensor IRE1 [11].  
In the present study, we showed that NO attenuates the ubiquitination of ERAD 
substrates (Fig. 1, 3). Additionally, we identified UBE2D1 as a novel S-nitrosylated 
protein. Specifically, we observed that UBE2D1 is S-nitrosylated at an active site 
residue, Cys85, a modification that is exposed to impair UBE2D1’s ubiquitin-binding 
activity (Fig. 2). Intriguingly, an examination of screening data for S-nitrosylated 
proteins reported by another group indicates that various E2 enzymes are similarly S-
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nitrosylated at their enzymatic active sites [27]. Additionally, UBE2D3, which belongs 
to the same family as UBE2D1, has been shown to be S-nitrosylated, a modification that 
decreases UBE2D3’s activation of chaperone-mediated LAMP2a-dependent autophagy 
[28]. In other work, we demonstrated that NO exacerbates ER stress via S-nitrosylation 
of the molecular chaperone PDI [8] and of the ER stress sensor IRE1 [11]. Collectively, 
these results indicate that many branches of responses against ER stress are weakened 
by nitrosative stress, prolonging ER stress by potentiating the accumulation of the 
unfolded proteins.  
Although further analysis is required, it is tempting to hypothesize that UBE2D1 
may transnitrosylate CHIP to propagate NO’s effect on ERAD. Transnitrosylation is a 
serial modification system that permits the transfer of NO from a given protein to other 
protein members of the same complex. As a result, transnitrosylation extends the range 
of processes controlled by SNO modification. Interestingly, CHIP, which is an E3 ligase 
of ERAD and functions downstream of UBE2D1, also is known to be S-nitrosylated 
[29]. In a chain reaction, E3 ligase activity might be attenuated to halt ERAD. Indeed, 
other groups have reported transnitrosylation [30, 31]. 
Our results show that nitrosative stress decreases the level of ubiquitinated protein. 
This observation contrasts with previous reports that the level of ubiquitinated proteins 
is increased in the brains of patients with neurodegenerative diseases such as PD [32], 
and AD [33]. However, one early-onset variant of PD, autosomal recessive PD (ARPD), 
results from Parkin loss-of-function mutations but is not associated with the 
accumulation of ubiquitin-positive aggregates in the brains of patients [34]. Other work 
has suggested that the formation of ubiquitin-positive aggresomes may play a protective 
role [35]. Although ubiquitylome analysis using the brains of AD patients revealed that 
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the ubiquitination levels of many proteins were increased, that report also showed that 
the level of the ubiquitination was decreased in certain proteins [35]. SGK1 might be 
one such protein. SGK1 phosphorylates tau at Ser214 [36], and this modification is 
correlated with the formation of paired helical filaments [37]. In this present study, we 
showed the ubiquitination of SGK1 is downregulated by nitrosative stress (Fig. 1); it is 
tempting to propose that nitrosative stress contributes to abnormal tau phosphorylation 
by leading to the accumulation of SGK1.  
Further analysis will be needed to investigate whether SNO-UBE2D1 contributes 
to the accumulation of ERAD substrates. Nonetheless, our data suggested that NO-
mediated ERAD inhibition results in an increase in the level of non-ubiquitinated 
unfolded proteins, a known mediator of neurotoxicity.  
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Figure 1. Effect of NO on the SGK1, ERAD substrate.  
A: HEK293T cells were transfected with Myc-SGK1 and incubated for 24 hr. 
Subsequently, the cells were treated with MG132 or LY294002 for 3 hr. B, C: (Upper) 
Myc-SGK1, T7-ubiquitin, and FLAG-UBE2D1 were co-expressed in HEK293T cells. 
At 24 hr after transfection, cells were co-treated with MG132 (25 M) and SNOC (200 
M, 2 hr) or GSNO (200 M, 3 hr). The control sample was treated with decayed (old) 
SNOC or GSH (reduced form of glutathione). Cell lysates were immunoprecipitated 
with anti-Myc antibody and subjected to western blotting with indicated antibodies. 
(Lower) The level of ubiquitinated SGK1 (indicated as [Ub]n-SGK1) was quantified 
within each sample and normalized to the level of non-ubiquitinated SGK1 within the 
respective sample. Data were analyzed using a two-tailed non-paired Student's t-test. 
Values are expressed as the mean ±S.E.M. (n=3); ** p<0.01 compared to treatment with 
old SNOC or GSH. 
 
Figure. 2. Identification of the S-nitrosylated ubiquitin-conjugating enzyme 
involved in ERAD. 
A: HEK293T cells were exposed to SNOC (200 M) for 30 min, and cell lysates were 
subjected to LC-MS/MS in conjunction with biotin-switch assays. MS/MS spectra 
yieled m/z peaks corresponding to UBE2D1 peptide fragments containing biotinylated 
Cys85. This analysis showed that UBE2D1 is S-nitrosylated at Cys85 by a physiological 
NO donor. B: The 3D structure of the complex of UBE2D1 and ubiquitin (PDB: 3PTF). 
The red circle show that ubiquitin binds to Cys85 of UBE2D1. C: HEK293T cells were 
transfected with FLAG-UBE2D1. At 24 hr after transfection, cells were treated with the 
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indicated concentrations of SNOC for 30 min. Cell lysates were subjected to a biotin-
switch assay to detect SNO-UBE2D1. D: The relative intensity of SNO-UBE2D1 in 
panel C was quantified and normalized to input UBE2D1. Data represent the fold 
increase of SNO-UBE2D1 in SNOC-treated cells compared to that in old-SNOC-treated 
cells using one-way ANOVA with post hoc Bonferroni’s test. Values are expressed as 
the mean ± S.E.M. (n=3); ** p<0.01 versus sample treated with old SNOC. 
 
Figure. 3. Treatments with NO donor attenuates the enzymatic activity of UBE2D1.  
A: A flow chart of the in vitro ubiquitination assay. UBE2D1 was pretreated with 
indicated concentrations of SNOC for 2 hr to promote formation of S-nitrosylated 
UBE2D1. B, C: Detection of ubiquitinated luciferase using anti-ubiquitin and anti-
luciferase antibodies. D: The level of ubiquitinated luciferase (indicated as [Ub]n) was 
quantified and normalized to the level in the control sample using one-way ANOVA 
with post hoc Bonferroni’s test. Data are expressed as the mean ±S.E.M. (n=4); ** 
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